Maxim Maintains Buy On Tekmira Following 3Q14 Results
Maxim Group analyst Jason Kolbert maintained a Buy rating on Tekmira Pharma (NASDAQ:TKMR) with a $31 price target, which represents a potential upside of 85% from where the stock is currently trading. The report follows the company third-quarter results, posting $4M in revenues, $11M in expenses, and $120M in cash on the balance sheet.
Kolbert noted, “DoD has exercised a $7M option to manufacture TKM-EBOLA-Guinea and the supply of the product (500 doses), which should be available in December 2014. Several Ebola-infected patients (primarily in the US) have been treated as part of emergency use granted by the FDA, though success or failure was not disclosed, and any success would not constitute a clinical trial. We expect TKM-EBOLA to be in clinical trials in 2015.
The analyst added, “TKM-HBV preclinical data showed rapid reduction in HBV surface antigen (HBsAg) across multiple genotypes, likely due to the promotion of seroconversion via attacking viral mRNA and preventing surplus viral proteins from dampening immune responses. TKM-HBV will go into clinical trials in 2015.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jason Kolbert has a total average return of 4.5% and a 42.1% success rate. Kolbert has a 22.4% average return when recommending TKMR, and is ranked #805 out of 3365 analysts.